Splenomegaly in myelofibrosis—new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors

Splenomegaly is a common sign of primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF), and post-essential thrombocythemia myelofibrosis (post-ET MF) that is associated with bothersome symptoms, which have a significant negative impact on patients’ quality of life. It may al...

Descripción completa

Detalles Bibliográficos
Autores principales: Randhawa, Jasleen, Ostojic, Alen, Vrhovac, Radovan, Atallah, Ehab, Verstovsek, Srdan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3464878/
https://www.ncbi.nlm.nih.gov/pubmed/22852872
http://dx.doi.org/10.1186/1756-8722-5-43

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3464878/
https://www.ncbi.nlm.nih.gov/pubmed/22852872
http://dx.doi.org/10.1186/1756-8722-5-43

Ejemplares similares